No increase in the prevalence of asthma, allergies, and atopic sensitisation among children in Germany: 1992–2001

I K Zöllner, S K Weiland, I Piechotowski, T Gabrio, E von Mutius, B Link, G Pfaff, B Kouros, J Wuthe

Background: From 1970 to 1990 increasing rates of asthma and allergic sensitisation were observed in several countries. The aim of this study was to investigate time trends in the prevalence of asthma and allergic sensitisation among school children in Germany between 1992 and 2001.

Methods: Parental reports of asthma, hay fever, and wheezing and measurements of specific serum IgE antibodies were investigated in six serial cross sectional surveys of 9–11 year old school children in three study areas in south west Germany.

Results: A total of 6762 school children of mean age 10 years (mean participation rate 77.9%) took part in the investigation in the three study areas. Over the 9 year study period no increase in the prevalence of current wheeze and asthma was observed. In addition, the prevalence of atopic sensitisation remained unchanged during the observation period.

Conclusions: These data, using parental reports and objective measures of allergy, suggest that there has been no further increase in the prevalence of asthma and atopy since 1992. The epidemic may thus have reached a plateau.

METHODS

Study design

Cross sectional surveys of 4th grade primary school children were conducted with identical study methods and instruments in three locations in Baden-Wuerttemberg: Mannheim, Kehl and Aulendorf/Bad Waldsee. Mannheim and Kehl are industrialised cities while Aulendorf/Bad Waldsee are more rural. The baseline surveys were conducted between October 1992 and March 1993, and then repeated five times during the same season in 1993/4, 1994/5, 1996/7, 1998/9, and 2000/1. Only children whose parents had given written informed consent participated. The study was coordinated by the Baden-Wuerttemberg State Health Office and approved by the ethics committee of the medical council of Baden-Wuerttemberg. The study sample was defined as all children with available data on sex, age, and residence in the study area for at least 2 years.

Questionnaire

A comprehensive questionnaire was distributed and filled in by the parents. Data on symptoms of asthma and hay fever were collected using questions from the International Study of Asthma and Allergies in Childhood (ISAAC). A doctor’s diagnosis was defined as an affirmative response to the question: “Has a doctor ever diagnosed one of the following diseases in your child? Asthma (yes/no); Hay fever (yes/no)”. In addition to health outcomes, potential confounding factors such as family history of atopy, number of siblings, parental education, breast feeding, and environmental tobacco smoke (ETS) were assessed via the questionnaires. All questions included in the analyses were asked in identical ways during the six surveys.

Serum samples

From 1992/3 to 1994/5 all school children whose parents gave their written informed consent underwent venous blood sampling. In the following surveys only a random subsample of the children whose parents had completed the questionnaire and given informed consent was invited to participate in the blood sampling for financial reasons. These children were identified during the examination according to a list of IDs which had been selected at random before the start of the field work. The proportion of children participating in the blood sampling among those invited to participate was calculated. A screening test for atopy (SX1, Pharmacia, Uppsala, Sweden) was used to detect specific IgE antibodies against a panel of aeroallergens (mixed grass pollen, birch pollen, mugwort pollen, Dermatophagoides pteronyssinus, cat dander, dog dander, Cladosporium herbarum) in the serum. The laboratory analyses were conducted in a central laboratory in Freiburg and, since 1996, in Stuttgart. Specific sensitisation was defined as a SX1 test above the detection limit (0.35 kU/l).
conducted stratified by nationality in order to avoid potential predictor of atopy in Germany, all further analyses were stable. However, the proportion of children without German nationality increased significantly from 17% at baseline to 28% in 2000/1. Since nationality is known to be a strong confounder. Nationality in Germany reflects ethnicity rather than place of birth. Among German children, a significant increase was seen in the prevalence of children with a family history of atopic disease, of high socioeconomic status, and of those who had been exclusively breast fed for at least 4 months (table 1).

There were no significant changes in the prevalence of symptoms and diagnoses of asthma and hay fever over time (table 2). For example, the prevalence of diagnosed asthma was 4.9%, 4.8%, 3.0%, 4.3%, 4.1%, and 5.6% during the six points in time among German children. In addition, the prevalence of atopic sensitisation remained unchanged during the observation period (34.1%, 29.9%, 36.3%, 36.4%, 35.7%, 34.7%). The adjusted odds ratios for changes over time were all very close to 1 and none showed a significant increase. In fact, the adjusted odds ratio for “wheeze ever” showed a significant decrease. None of the factors considered was found to have a substantial influence on the time trends in the multivariate analyses. There was no evidence for differences in time trends by sex, family history of atopy, and presence of atopic sensitisation. The respective prevalence rates among the children without German nationality were generally lower, but no significant changes over time were observed.

**DISCUSSION**

Before interpreting the findings, the strengths and limitations of our study have to be addressed. The same

### Table 1 Characteristics of the study populations

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Addressed</td>
<td>1410</td>
<td>1382</td>
<td>1402</td>
<td>1513</td>
<td>1500</td>
<td>1548</td>
</tr>
<tr>
<td>Questionnaires completed</td>
<td>1077</td>
<td>1079</td>
<td>1078</td>
<td>1171</td>
<td>1197</td>
<td>1160</td>
</tr>
<tr>
<td>Participation rate</td>
<td>76.4%</td>
<td>82.4%</td>
<td>76.9%</td>
<td>73.3%</td>
<td>79.8%</td>
<td>74.9%</td>
</tr>
<tr>
<td>Study sample*</td>
<td>919</td>
<td>955</td>
<td>930</td>
<td>1030</td>
<td>1036</td>
<td>1070</td>
</tr>
<tr>
<td>Serum samples</td>
<td>798</td>
<td>763</td>
<td>832</td>
<td>674</td>
<td>722</td>
<td>653</td>
</tr>
<tr>
<td>Participation in blood sampling†</td>
<td>86.8%</td>
<td>79.9%</td>
<td>89.5%</td>
<td>78.4%</td>
<td>82.4%</td>
<td>93.4%</td>
</tr>
<tr>
<td>Mean (SD) age (years)</td>
<td>10.4 (0.6)</td>
<td>10.3 (0.6)</td>
<td>10.3 (0.6)</td>
<td>10.2 (0.6)</td>
<td>10.2 (0.6)</td>
<td>10.2 (0.5)</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>457 (51%)</td>
<td>474 (50%)</td>
<td>450 (48%)</td>
<td>524 (51%)</td>
<td>519 (50%)</td>
<td>503 (47%)</td>
</tr>
<tr>
<td>German nationality</td>
<td>761 (85%)</td>
<td>731 (77%)</td>
<td>670 (72%)</td>
<td>717 (70%)</td>
<td>739 (71%)</td>
<td>772 (72%)</td>
</tr>
<tr>
<td>German children only</td>
<td>145 (19%)</td>
<td>196 (27%)</td>
<td>145 (22%)</td>
<td>170 (24%)</td>
<td>194 (26%)</td>
<td>212 (27%)</td>
</tr>
<tr>
<td>SES hight</td>
<td>405 (53%)</td>
<td>360 (49%)</td>
<td>348 (52%)</td>
<td>350 (50%)</td>
<td>356 (48%)</td>
<td>350 (50%)</td>
</tr>
<tr>
<td>No of siblings ≥2</td>
<td>297 (39%)</td>
<td>264 (36%)</td>
<td>251 (37%)</td>
<td>263 (37%)</td>
<td>278 (38%)</td>
<td>298 (39%)</td>
</tr>
<tr>
<td>Familial history of asthma, atopic eczema or hay fever</td>
<td>221 (29%)</td>
<td>243 (33%)</td>
<td>239 (36%)</td>
<td>241 (34%)</td>
<td>269 (36%)</td>
<td>283 (37%)</td>
</tr>
<tr>
<td>Breast feeding</td>
<td>158 (21%)</td>
<td>149 (20%)</td>
<td>174 (26%)</td>
<td>220 (31%)</td>
<td>246 (33%)</td>
<td>255 (33%)</td>
</tr>
</tbody>
</table>

*All children with known sex, age and residence for at least 2 years in study area.
†Proportion of children participating in blood sampling of those invited to participate (these were random subsamples after 1995).
*Environmental tobacco smoke (ETS) defined as any passive smoke exposure in the home.

### Table 2 Prevalence of asthma and allergies among German children living in three different areas: 1992–2001

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Questionnaires</td>
<td>N=761</td>
<td>N=731</td>
<td>N=670</td>
<td>N=717</td>
<td>N=739</td>
<td>N=772</td>
</tr>
<tr>
<td>Diagnoses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>37 (4.9%)</td>
<td>35 (4.8%)</td>
<td>20 (3.0%)</td>
<td>31 (4.3%)</td>
<td>30 (4.1%)</td>
<td>43 (5.6%)</td>
</tr>
<tr>
<td>Hay fever</td>
<td>58 (7.6%)</td>
<td>47 (6.4%)</td>
<td>52 (7.8%)</td>
<td>58 (8.1%)</td>
<td>62 (8.6%)</td>
<td>70 (9.1%)</td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wheeze ever</td>
<td>233 (30.6%)</td>
<td>228 (31.2%)</td>
<td>205 (30.6%)</td>
<td>201 (28.0%)</td>
<td>205 (27.7%)</td>
<td>240 (31.1%)</td>
</tr>
<tr>
<td>Wheeze in past 12 months</td>
<td>72 (9.5%)</td>
<td>80 (10.9%)</td>
<td>58 (8.7%)</td>
<td>68 (9.5%)</td>
<td>73 (9.9%)</td>
<td>81 (10.5%)</td>
</tr>
<tr>
<td>Runny nose/itchy eyes</td>
<td>70 (9.2%)</td>
<td>69 (9.4%)</td>
<td>70 (10.4%)</td>
<td>59 (8.2%)</td>
<td>58 (7.8%)</td>
<td>79 (10.2%)</td>
</tr>
<tr>
<td>Serum analyses</td>
<td>N=649</td>
<td>N=606</td>
<td>N=600</td>
<td>N=547</td>
<td>N=552</td>
<td>N=479</td>
</tr>
<tr>
<td>Specific IgE (SX1)††</td>
<td>221 (34.1%)</td>
<td>181 (29.9%)</td>
<td>218 (36.3%)</td>
<td>181 (36.4%)</td>
<td>197 (35.7%)</td>
<td>166 (34.7%)</td>
</tr>
</tbody>
</table>

*Adjusted for sex, family history of atopic diseases, socioeconomic status, breast feeding, passive smoking, number of siblings, place of living, dampness.
††SX1: specific IgE against a panel of aeroallergens (mixed grass pollen, birch pollen, mugwort pollen, Dermatophagoides pteronyssinus, cat dander, dog dander, Cladosporium herbarum).
standardised study methods and instruments were used in all six surveys. The participation rates remained stable over time. Moreover, all populations were investigated at six different points in time over a span of 9 years. Most other studies assessing temporal changes in the prevalence of asthma and allergies included only two or, at the most, three surveys over time.1 3 5 Additional measurement points give a much more robust estimate of underlying trends. The three locations allowed assessment of consistency across populations which was, in fact, observed. An additional major strength of the study is the fact that objective measurements of allergen specific serum IgE levels were included. It has been argued that trend data which rely exclusively on questionnaire information are subject to reporting bias due to changes in diagnostic habits and perception of disease.12 The measurements of serum IgE levels were conducted using a well established and reliable method.

The study areas were selected a priori with regard to air pollution exposure and may not be representative of the whole of Germany. However, the areas of Mannheim and Kehl are comparable to many other industrial areas in Germany, and the rural areas have no specific characteristics limiting the generalisability of the findings. The sample size and length of the observation period was substantial but may have been insufficient to pick up trends in certain subgroups. Although an objective marker of allergy was measured, no pulmonary function testing including airway challenge was performed to support the asthma prevalence estimates. There is, however, no gold standard for a diagnosis of asthma, but previous studies have shown good validity for a physician’s diagnosis of asthma.13

Numerous studies have reported an increase in the prevalence of asthma and allergies over many decades in the 20th century. Although most studies relied on questionnaire data, the observations have been supported by serial prevalence studies which also used objective measurements of allergy.1 14 While it has been widely accepted that the prevalence of asthma and allergies has increased in the past decades in many western countries, the question arose as to when the epidemic would eventually reach a plateau or start to decrease.

The data presented here show no further increase in the prevalence of symptoms and diagnoses of childhood asthma and allergies between 1992 and 2001. It is important that the prevalence of atopic sensitisation also remained unchanged during the study period. Data on time trends in the prevalence of asthma and atopy in Germany before 1992 are unfortunately not available. It is, however, very likely that increases in the prevalence of asthma and atopy observed before 1992 in many countries also occurred in Germany, and evidence from comparisons between East and West Germany suggests that this occurred particularly among those born after 1960 in the West.14 15 Our findings of no increase since 1992 are in line with reports from Italy.16 Ronchetti and colleagues reported an increase in the prevalence of asthma among school children in Rome between 1974 and 1992 but no further increase between 1992 and 1998. While the later period was rather short, it is of interest that other recent studies found similar results. A halt in the increase of prevalence rates during the 1990s was observed in both Swiss and Australian children.16 17 Both studies also included objective measurements—serum IgE levels in Switzerland and airway responsiveness in Australia—which confirmed the lack of temporal change. Questionnaire based surveys from the UK and China observed decreases in the prevalence of asthma symptoms between the end of the 20th century and the beginning of this century.16 18 A British study on asthma episodes prompted consultation with general practitioners also observed a downward trend since 1993.19

Our findings are therefore in line with those of several others and support the notion that the international epidemic of asthma and allergies may have started to level off during the 1990s, at least in some areas of the western world.20 It is not clear which factors are responsible for these changes. Our investigation, like others,16 20 did not allow study of the changing trends by specific risk factors. It is possible that a combination of various factors such as nutrition, microbial exposures, early life infections, housing conditions, exposure to outdoor pollutants such as diesel, allergen exposure, and others may have affected the temporal trends.20 21

ACKNOWLEDGEMENTS

The authors thank M Schwenk for very helpful discussions; A Felder-Kennel, M Schrömpf, and V Maienser for their work in the field investigations; U Weidner, G Korb, G Horras-Hun, S Broser, E Rzonca, and G Kirsch for their excellent technical assistance; and E Schindler and H Knebel for documenting and preparing the data for analysis.

Authors’ affiliations

I K Zöllner, I Piechotowski, T Gabrio, B Link, G Pfaff, J Wuthe, Baden-Wuerttemberg State Health Office, Stuttgart, Germany
S K Weiland, Department of Epidemiology, University of Ulm, Ulm, Germany
E von Mutius, Von Haunersches Kinderspital, University of Munich, Munich, Germany
B Kouros, Baden-Wuerttemberg Ministry of Social Affairs, Germany

Competing interests: none declared

REFERENCES


www.thoraxjnl.com
LUNG ALERT

PaCO₂: a marker of severity in community acquired pneumonia


Arterial carbon dioxide tension (PaCO₂) has not previously been studied in detail as a predictor of mortality in patients with community acquired pneumonia. This retrospective Canadian study examined the relationship between PaCO₂ and in-hospital mortality in patients with community acquired pneumonia.

Of the 2171 study subjects, in-hospital mortality (10%) was greater in those with hypocapnia (PaCO₂ <32 mm Hg) (OR 1.8 (95% CI 1.0 to 3.2)) and hypercapnia (PaCO₂ >45 mm Hg) (OR 2.6 (95% CI 1.5 to 4.5)) than in those with normal PaCO₂ values (40–44 mm Hg). In-hospital mortality rates within these PaCO₂ bands were similar for patients with and without chronic obstructive pulmonary disease (COPD). However, COPD was more common in those with hypercapnia and bacteremia was more common in those with hypcapnia. For patients without bacteremia, mortality was 2.5 times higher in those with hypercapnia but was not greater in those with hypcapnia, raising the possibility that bacteremia may be the leading cause of death in hypcapnic patients. Respiratory rate was only loosely correlated with PaCO₂ levels and did not increase in-hospital mortality rates. Surprisingly, markers of renal function, blood pressure, age, and respiratory rate did not correlate with mortality rates.

This shows that PaCO₂ levels are another marker of in-hospital mortality in community acquired pneumonia and could be used to risk stratify patients on admission. However, the study did not show the mode of death in these patients. Further assessment is required to establish whether PaCO₂ levels add value over and above routinely assessed clinical and laboratory parameters.

P Palchaudhuri
Senior House Officer, Department of Infection, Immunity and Thoracic Medicine, Royal Free Hospital, London, UK; paramita03@rediffmail.com
(95% CI 1.29 to 6.42), p<0.0069; table 1) with a PAR for AA homozygotes and AG heterozygotes of 50%.
This study underlines the importance of the association between the BTNL2 rs2076530 variant with the susceptibility to develop sarcoidosis in a German population. Furthermore, our data suggest that susceptibility is preferentially towards the chronic form of the disease.

Y Li, B Wollnik
Center for Molecular Medicine Cologne (CMMC) and Institute of Human Genetics, University of Cologne, Germany

S Pabst, M Lennarz
Medizinische Universita¨tt Poliklinik, Rheinische-Friedrichs-Universita¨t Bonn, Germany

E Rohmann
Center for Molecular Medicine Cologne (CMMC) and Institute of Human Genetics, University of Cologne, Germany

A Gillissen
Sta¨dtisches Klinikum St Georg, Leipzig, Germany

H Vetter, C Gro¨h
Medizinische Universita¨tt Poliklinik, Rheinische-Friedrichs-Universita¨t Bonn, Germany

Correspondence to: Professor Dr med C Gro¨h, Medizinische Universita¨t Poliklinik, Wilhelmstr. 35-37, D-53111 Bonn, Germany, c.grohe@uni-bonn.de

doi: 10.1136/thx.2005.056564

Competing interests: none.

References

Asthma and allergies in Germany
We read the study by Zoll¨ner and colleagues published recently in Thorax about the leveling off of asthma and allergies among children in Germany between 1992 and 2001.1 We have published a study looking at the same issue and using a similar protocol (ISAGA)3 to assess the symptoms, diagnosis, and severity of asthma and allergies in more than 15000 children aged 6–7 and 13–14 years between 1995 and 2000 in Mu¨nster, Germany.1 We found a tendency towards an increase in current symptoms of asthma and allergies in both age groups, but more so among girls.

Table 1

<table>
<thead>
<tr>
<th></th>
<th>Co-dominant</th>
<th>Dominant (AA/AG v GG)</th>
<th>Recessive (AA v AG/GG)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AA</td>
<td>AG</td>
<td>GG</td>
</tr>
<tr>
<td>Controls</td>
<td>84 (41%)</td>
<td>82 (41%)</td>
<td>36 (18%)</td>
</tr>
<tr>
<td>Cases</td>
<td>99 (47%)</td>
<td>93 (44%)</td>
<td>18 (9%)</td>
</tr>
<tr>
<td>Acute</td>
<td>30 (42%)</td>
<td>32 (45%)</td>
<td>9 (13%)</td>
</tr>
<tr>
<td>Chronic</td>
<td>59 (52%)</td>
<td>47 (41%)</td>
<td>8 (7%)</td>
</tr>
</tbody>
</table>

Significant associations are shown in bold.

W Maziak, U Keil
Institute of Epidemiology and Social Medicine, University Clinic of Muenster, Muenster, Germany; maziak@net.sy

Authors’ reply
Unfortunately, the paper by Maziak et al published in Allergy was listed as reference number 18 instead of number 21 in the reference list of our paper. The effect found in 13–14 year old girls could also be due to a former underdiagnosis of asthma in girls, as discussed in their paper.

In our results are based on six cross sectional surveys, we consider the title and the conclusion—that we did not see an increase in asthma and allergies from 1992 to 2001—to be appropriate.

I Zoll¨ner
Department of Epidemiology and Health Reporting, Baden-Wu¨rttemberg State Health Office, Wiedenholdstr 15, D-70174 Stuttgart, Germany; iris.zollner@bps.bwl.de

In the paper entitled “No increase in the prevalence of asthma, allergies, and atopic sensitisation among children in Germany: 1992–2001” by I K Zoll¨ner et al which appeared in the July 2005 issue of Thorax (2005;60:545–8), the authors apologise for a mistake which occurred in the reference list. Reference number 18 should be number 21 and references 19–21 should be listed as 18–20.

doi: 10.1136/thx.2005.040444corr1

The paper entitled “Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analyses” by G J Rodrigo and J A Castro-Rodriguez (10.1136/thx.2005.04044) has been published previously on 17 June 2005 as a Thorax Online First article but under the incorrect DOI (10.1136/thx.2005.047803). The publishers apologise for this error. The definitive version of the article can be found at the following citation: Thorax 2005;60:740–6.

doi: 10.1136/thx.2005.040881corr1

In the paper entitled “Hormone replacement therapy, body mass index and asthma in perimenopausal women: a cross sectional survey” by F Gomez Real et al published in the January 2006 issue of Thorax (2006;61:34–40), the fourth author should be K A Franklin, not K Franklin.